• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    5/20/25 7:30:06 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email
    6-K 1 f6k_052025.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-39152

    Quantum BioPharma Ltd.
    (Translation of registrant's name into English)

    55 University Ave., Suite 1003
    Toronto, Ontario M5J2H7, Canada

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Quantum BioPharma Ltd.    
      (Registrant)
       
      
    Date: May 20, 2025     /s/ Donal Carroll    
      Donal Carroll
      Chief Financial Officer
      


    EXHIBIT INDEX

     

    Exhibit Number Description
      
    99.1 Press Release dated May 20, 2025

    Get the next $QNTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    SEC Filings

    See more
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      6/13/25 7:00:05 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      6/10/25 8:00:24 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Quantum Biopharma Ltd.

      6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

      6/3/25 7:50:06 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

      TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the "CVRs") to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares. Each CVR will entitle the holder to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds, ultimately recovered by the Company, if any, in connection with its legal action against CIBC World Markets, RBC D

      6/13/25 7:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000

      TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased additional Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $5,000,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency. This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment

      6/10/25 8:00:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma Clarifies It Has Not Changed Its Name

      TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name. In addition, it has been brought to the attention of Quantum BioP

      6/3/25 7:50:00 AM ET
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care